BioSpace News Archive

Arrowhead Pharmaceuticals, Inc. announced that as an inducement to entering into employment with the Company, on December 28, 2023, the Company’s Board of Directors approved “inducement” grants to 32 new employees under Rule 5635 of the NASDAQ Listing Rules.

LumiraDx Limited, a next generation point of care diagnostics company, announced the appointment of joint administrators for two of its subsidiaries.

Pyxis Oncology, Inc. reported that Pyxis Oncology’s Compensation Committee of the Board of Directors approved a stock option grant to Ken Kobayashi, M.D., the Company’s newly appointed Chief Medical Officer, in connection with his employment with the Company effective on November 27, 2023.

Valneva SE, a specialty vaccine company, announced that the Company is modifying its financial guidance for 2023.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced it granted an inducement award on December 29, 2023.

MiMedx Group, Inc. provided the following update regarding AXIOFILL and reiterated its outlook for 2023 full year net sales growth and fourth quarter adjusted EBITDA margin.

Sarepta Therapeutics, Inc. granted equity awards on December 29, 2023 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 4 individuals hired by Sarepta in December 2023.

MedMira Inc., reported on its financial results for the quarter ended October 31, 2023.

United Therapeutics Corporation, a public benefit corporation, announced that Dr. Martine Rothblatt, Chairperson and Chief Executive Officer, will provide an overview and update on the company’s business during a presentation at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco.

Antibe Therapeutics Inc. is pleased to announce an Early Warrant Exercise Incentive Program for its 6.5 million outstanding and unlisted share purchase warrants having an exercise price of $1.50 and expiring on July 31, 2024.